Bridgeway Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Bridgeway Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$470K	Hold	176,171	–	–	0.01%	859
2026 Q1	$416K	Buy	176,171 +6,000	+4%	+$15.3K	0.01%	851
2025 Q4	$359K	Sell	170,171 -20,000	-11%	-$39.7K	0.01%	887
2025 Q3	$325K	Buy	190,171 +75,000	+65%	+$104K	0.01%	901
2025 Q2	$134K	Hold	115,171	–	–	﹤0.01%	1030
2025 Q1	$127K	Sell	115,171 -18,829	-14%	-$26.9K	﹤0.01%	998
2024 Q4	$230K	Sell	134,000 -3,400	-2%	-$8.19K	0.01%	975
2024 Q3	$341K	Sell	137,400 -11,000	-7%	-$29.8K	0.01%	949
2024 Q2	$359K	Hold	148,400	–	–	0.01%	931
2024 Q1	$601K	Buy	+148,400	New	+$559K	0.01%	875
2023 Q4	–	Sell	-115,033	Closed	-$477K	–	1356
2023 Q3	$477K	Sell	115,033 -27,800	-19%	-$172K	0.01%	888
2023 Q2	$687K	Buy	142,833 +25,000	+21%	+$120K	0.02%	822
2023 Q1	$478K	Buy	117,833 +34,233	+41%	+$179K	0.01%	900
2022 Q4	$451K	Hold	83,600	–	–	0.01%	909
2022 Q3	$839K	Buy	83,600 +2,800	+3%	+$16.1K	0.02%	771
2022 Q2	$380K	Sell	80,800 -49,600	-38%	-$186K	0.01%	939
2022 Q1	$510K	Buy	+130,400	New	+$709K	0.01%	926

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Bridgeway Capital Management's ABOS Position: Q2 2026 in Review

Bridgeway Capital Management held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 176,171 shares worth $470K. The position accounts for 0.01% of the portfolio, ranked #859.

Bridgeway Capital Management first reported a position in ABOS in Q1 2022 and has held it in 17 quarters since. The position peaked at $839K in Q3 2022. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Bridgeway Capital Management held 176,171 shares of Acumen Pharmaceuticals worth $470K as of Q2 2026.
Bridgeway Capital Management left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
Acumen Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #859 holding.
Bridgeway Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
Bridgeway Capital Management's Acumen Pharmaceuticals position peaked at $839K in Q3 2022.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.